Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), and Sanofi (SNA) Tuesday said the Phase 2b RELIEVE UCCD study of duvakitug met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD), the two main types of inflammatory bowel disease (IBD). Teva shares were more than 22 percent up in pre-market trading.
In October last year, Teva and Sanofi had signed an agreement to co-develop and co-commercialize Teva's duvakitug, for which Teva received an upfront payment of $500 million.
In the RELIEVE UCCD study, 36.2 percent of UC patients treated with low dose of duvakitug, and 47.8 percent of patients treated with high dose, achieved clinical remission compared to 20.45 percent who were on placebo. In pateitns with CD, 26.1 percent treated with low dose and 47.8 percent treated with high dose achieved endoscopic response compared to 13 percent on placebo.
Further, duvakitug was generally well tolerated in both UC and CD with no safety signal identified.
Teva stock had closed at $16.51, up 0.06 percent on Monday. It has traded in the range of $10.13 - 19.31 in the last 1 year.
For comments and feedback: editorial@rttnews.com